Annual CFO
-$14.30 M
-$2.22 M-18.42%
31 March 2024
Summary:
Portage Biotech annual cash flow from operations is currently -$14.30 million, with the most recent change of -$2.22 million (-18.42%) on 31 March 2024. During the last 3 years, it has fallen by -$10.01 million (-233.73%). PRTG annual CFO is now -9632.47% below its all-time high of -$146.90 thousand, reached on 31 March 2003.PRTG Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.56 M
+$126.00 K+7.47%
30 September 2024
Summary:
Portage Biotech quarterly cash flow from operations is currently -$1.56 million, with the most recent change of +$126.00 thousand (+7.47%) on 30 September 2024. Over the past year, it has increased by +$2.73 million (+63.65%). PRTG quarterly CFO is now -114.43% below its all-time high of $10.81 million, reached on 31 December 2009.PRTG Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$9.80 M
+$2.73 M+21.80%
30 September 2024
Summary:
Portage Biotech TTM cash flow from operations is currently -$9.80 million, with the most recent change of +$2.73 million (+21.80%) on 30 September 2024. Over the past year, it has increased by +$5.33 million (+35.24%). PRTG TTM CFO is now -194.93% below its all-time high of $10.32 million, reached on 31 December 2009.PRTG TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRTG Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.4% | +63.6% | +35.2% |
| 3 y3 years | -233.7% | -22.4% | -114.6% |
| 5 y5 years | -1566.3% | -25.5% | -261.8% |
PRTG Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -233.7% | at low | -22.4% | +66.7% | -114.6% | +38.2% |
| 5 y | 5 years | -1566.3% | at low | -140.0% | +66.7% | -261.8% | +38.2% |
| alltime | all time | -9632.5% | at low | -114.4% | +85.5% | -194.9% | +38.2% |
Portage Biotech Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.56 M(-7.5%) | -$9.80 M(-21.8%) |
| June 2024 | - | -$1.69 M(-46.0%) | -$12.53 M(-12.4%) |
| Mar 2024 | -$14.30 M(+18.4%) | -$3.12 M(-9.0%) | -$14.30 M(-9.8%) |
| Dec 2023 | - | -$3.43 M(-20.1%) | -$15.86 M(+4.8%) |
| Sept 2023 | - | -$4.29 M(+24.3%) | -$15.13 M(+13.3%) |
| June 2023 | - | -$3.45 M(-26.2%) | -$13.35 M(+10.6%) |
| Mar 2023 | -$12.07 M(+78.5%) | -$4.68 M(+73.1%) | -$12.07 M(+25.2%) |
| Dec 2022 | - | -$2.70 M(+7.6%) | -$9.64 M(+12.2%) |
| Sept 2022 | - | -$2.51 M(+15.4%) | -$8.60 M(+16.8%) |
| June 2022 | - | -$2.18 M(-3.3%) | -$7.36 M(+8.8%) |
| Mar 2022 | -$6.76 M(+57.9%) | -$2.25 M(+35.8%) | -$6.76 M(+24.6%) |
| Dec 2021 | - | -$1.66 M(+30.0%) | -$5.43 M(+18.9%) |
| Sept 2021 | - | -$1.27 M(-19.3%) | -$4.57 M(-11.8%) |
| June 2021 | - | -$1.58 M(+72.3%) | -$5.18 M(+20.8%) |
| Mar 2021 | -$4.28 M(+15.3%) | -$917.00 K(+15.5%) | -$4.28 M(+1.8%) |
| Dec 2020 | - | -$794.00 K(-57.9%) | -$4.21 M(+3.5%) |
| Sept 2020 | - | -$1.89 M(+174.0%) | -$4.07 M(+18.8%) |
| June 2020 | - | -$688.00 K(-18.3%) | -$3.42 M(-7.8%) |
| Mar 2020 | -$3.71 M(+332.9%) | -$842.00 K(+29.5%) | -$3.71 M(+14.1%) |
| Dec 2019 | - | -$650.00 K(-47.7%) | -$3.25 M(+20.2%) |
| Sept 2019 | - | -$1.24 M(+27.0%) | -$2.71 M(+63.9%) |
| June 2019 | - | -$979.00 K(+156.3%) | -$1.65 M(+92.5%) |
| Mar 2019 | -$858.00 K(-20.0%) | -$382.00 K(+267.3%) | -$858.00 K(+24.7%) |
| Dec 2018 | - | -$104.00 K(-44.4%) | -$688.00 K(-27.3%) |
| Sept 2018 | - | -$187.00 K(+1.1%) | -$947.00 K(-6.3%) |
| June 2018 | - | -$185.00 K(-12.7%) | -$1.01 M(-5.8%) |
| Mar 2018 | -$1.07 M(-18.8%) | -$212.00 K(-41.6%) | -$1.07 M(-147.6%) |
| Dec 2017 | - | -$363.00 K(+44.6%) | $2.25 M(-6.1%) |
| Sept 2017 | - | -$251.00 K(+1.6%) | $2.40 M(+55.1%) |
| June 2017 | - | -$247.00 K(-107.9%) | $1.55 M(-217.3%) |
| Mar 2017 | -$1.32 M(-77.4%) | $3.12 M(-1542.6%) | -$1.32 M(-76.8%) |
| Dec 2016 | - | -$216.00 K(-80.4%) | -$5.69 M(-17.0%) |
| Sept 2016 | - | -$1.10 M(-64.6%) | -$6.85 M(-15.1%) |
| June 2016 | - | -$3.12 M(+149.4%) | -$8.07 M(+38.2%) |
| Mar 2016 | -$5.84 M(+123.4%) | -$1.25 M(-9.5%) | -$5.84 M(+4.3%) |
| Dec 2015 | - | -$1.38 M(-40.6%) | -$5.60 M(+20.2%) |
| Sept 2015 | - | -$2.32 M(+162.2%) | -$4.66 M(+49.3%) |
| June 2015 | - | -$885.90 K(-12.1%) | -$3.12 M(+19.3%) |
| Mar 2015 | -$2.61 M(+35.1%) | -$1.01 M(+129.4%) | -$2.61 M(-6.2%) |
| Dec 2014 | - | -$439.20 K(-44.0%) | -$2.79 M(+8.4%) |
| Sept 2014 | - | -$784.60 K(+105.2%) | -$2.57 M(+22.5%) |
| June 2014 | - | -$382.30 K(-67.6%) | -$2.10 M(+8.4%) |
| Mar 2014 | -$1.94 M(+8.0%) | -$1.18 M(+429.3%) | -$1.94 M(-348.2%) |
| Dec 2013 | - | -$223.00 K(-28.6%) | $779.70 K(+16.5%) |
| Sept 2013 | - | -$312.40 K(+42.3%) | $669.30 K(-77.2%) |
| June 2013 | - | -$219.60 K(-114.3%) | $2.93 M(-263.6%) |
| Mar 2013 | -$1.79 M | $1.53 M(-560.3%) | -$1.79 M(-49.9%) |
| Dec 2012 | - | -$333.40 K(-117.1%) | -$3.57 M(+1.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $1.95 M(-139.4%) | -$3.52 M(-39.1%) |
| June 2012 | - | -$4.94 M(+1905.2%) | -$5.77 M(+330.9%) |
| Mar 2012 | -$1.34 M(-48.9%) | -$246.50 K(-10.7%) | -$1.34 M(+35.5%) |
| Dec 2011 | - | -$275.90 K(-10.5%) | -$988.90 K(-16.0%) |
| Sept 2011 | - | -$308.20 K(-39.5%) | -$1.18 M(-29.8%) |
| June 2011 | - | -$509.40 K(-587.0%) | -$1.68 M(-36.1%) |
| Mar 2011 | -$2.62 M(+637.0%) | $104.60 K(-122.6%) | -$2.62 M(-80.5%) |
| Dec 2010 | - | -$463.60 K(-42.6%) | -$13.48 M(+509.7%) |
| Sept 2010 | - | -$807.70 K(-44.6%) | -$2.21 M(+28.8%) |
| June 2010 | - | -$1.46 M(-86.4%) | -$1.72 M(+382.1%) |
| Mar 2010 | -$356.10 K(+23.9%) | -$10.76 M(-199.5%) | -$356.10 K(-103.4%) |
| Dec 2009 | - | $10.81 M(-3556.8%) | $10.32 M(-2179.8%) |
| Sept 2009 | - | -$312.70 K(+222.7%) | -$496.30 K(+77.3%) |
| June 2009 | - | -$96.90 K(+24.1%) | -$279.90 K(-2.6%) |
| Mar 2009 | -$287.40 K(-38.7%) | -$78.10 K(+808.1%) | -$287.30 K(+8.3%) |
| Dec 2008 | - | -$8600.00(-91.1%) | -$265.40 K(-24.8%) |
| Sept 2008 | - | -$96.30 K(-7.7%) | -$353.10 K(-11.7%) |
| June 2008 | - | -$104.30 K(+85.6%) | -$400.00 K(-14.7%) |
| Mar 2008 | -$468.90 K(+2.2%) | -$56.20 K(-41.6%) | -$468.90 K(-24.2%) |
| Dec 2007 | - | -$96.30 K(-32.8%) | -$618.70 K(+29.8%) |
| Sept 2007 | - | -$143.20 K(-17.3%) | -$476.50 K(+47.0%) |
| June 2007 | - | -$173.20 K(-15.9%) | -$324.10 K(-29.4%) |
| Mar 2007 | -$458.80 K(-28.9%) | -$206.00 K(-548.8%) | -$458.90 K(+499.1%) |
| Dec 2006 | - | $45.90 K(+398.9%) | -$76.60 K(-78.9%) |
| Sept 2006 | - | $9200.00(-103.0%) | -$363.70 K(-16.5%) |
| June 2006 | - | -$308.00 K(-274.7%) | -$435.50 K(-32.5%) |
| Mar 2006 | -$645.50 K(+100.8%) | $176.30 K(-173.1%) | -$645.50 K(-21.5%) |
| Dec 2005 | - | -$241.20 K(+285.3%) | -$821.80 K(+23.0%) |
| Sept 2005 | - | -$62.60 K(-87.9%) | -$668.30 K(-9.3%) |
| June 2005 | - | -$518.00 K(+490.6%) | -$736.50 K(-10.0%) |
| Dec 2004 | - | -$87.70 K(-33.0%) | -$818.20 K(+5.6%) |
| Sept 2004 | - | -$130.80 K(-62.3%) | -$774.50 K(+18.7%) |
| June 2004 | - | -$346.70 K(+37.0%) | -$652.60 K(+103.0%) |
| Mar 2004 | -$321.50 K(+118.9%) | -$253.00 K(+475.0%) | -$321.40 K(+344.5%) |
| Dec 2003 | - | -$44.00 K(+394.4%) | -$72.30 K(-8.6%) |
| Sept 2003 | - | -$8900.00(-42.6%) | -$79.10 K(-31.3%) |
| June 2003 | - | -$15.50 K(+297.4%) | -$115.20 K(-21.5%) |
| Mar 2003 | -$146.90 K(-6.3%) | -$3900.00(-92.3%) | -$146.80 K(-37.7%) |
| Dec 2002 | - | -$50.80 K(+12.9%) | -$235.70 K(-0.8%) |
| Sept 2002 | - | -$45.00 K(-4.5%) | -$237.60 K(+25.4%) |
| June 2002 | - | -$47.10 K(-49.2%) | -$189.50 K(+20.9%) |
| Mar 2002 | -$156.80 K(-54.8%) | -$92.80 K(+76.1%) | -$156.80 K(+145.0%) |
| Dec 2001 | - | -$52.70 K(-1800.0%) | -$64.00 K(+466.4%) |
| Sept 2001 | - | $3100.00(-121.5%) | -$11.30 K(-21.5%) |
| June 2001 | - | -$14.40 K | -$14.40 K |
| Mar 2001 | -$347.00 K(-19.1%) | - | - |
| Mar 2000 | -$428.80 K(+26.6%) | - | - |
| Mar 1999 | -$338.80 K(-19.9%) | - | - |
| Mar 1998 | -$423.00 K | - | - |
FAQ
- What is Portage Biotech annual cash flow from operations?
- What is the all time high annual CFO for Portage Biotech?
- What is Portage Biotech annual CFO year-on-year change?
- What is Portage Biotech quarterly cash flow from operations?
- What is the all time high quarterly CFO for Portage Biotech?
- What is Portage Biotech quarterly CFO year-on-year change?
- What is Portage Biotech TTM cash flow from operations?
- What is the all time high TTM CFO for Portage Biotech?
- What is Portage Biotech TTM CFO year-on-year change?
What is Portage Biotech annual cash flow from operations?
The current annual CFO of PRTG is -$14.30 M
What is the all time high annual CFO for Portage Biotech?
Portage Biotech all-time high annual cash flow from operations is -$146.90 K
What is Portage Biotech annual CFO year-on-year change?
Over the past year, PRTG annual cash flow from operations has changed by -$2.22 M (-18.42%)
What is Portage Biotech quarterly cash flow from operations?
The current quarterly CFO of PRTG is -$1.56 M
What is the all time high quarterly CFO for Portage Biotech?
Portage Biotech all-time high quarterly cash flow from operations is $10.81 M
What is Portage Biotech quarterly CFO year-on-year change?
Over the past year, PRTG quarterly cash flow from operations has changed by +$2.73 M (+63.65%)
What is Portage Biotech TTM cash flow from operations?
The current TTM CFO of PRTG is -$9.80 M
What is the all time high TTM CFO for Portage Biotech?
Portage Biotech all-time high TTM cash flow from operations is $10.32 M
What is Portage Biotech TTM CFO year-on-year change?
Over the past year, PRTG TTM cash flow from operations has changed by +$5.33 M (+35.24%)